Erythropoietin both protects from and reverses experimental diabetic neuropathy
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Erythropoietin (EPO) possesses generalized neuroprotective and neurotrophic actions. We tested the efficacy of recombinant human EPO (rhEPO) in preventing and reversing nerve dysfunction in streptozotocin (STZ)-induced diabetes in rats. Two days after STZ [60 mg/kg of body weight (b.w.), i.p.], diabetic animals were administered rhEPO (40 μg/kg of b.w.) three times weekly for 5 weeks either immediately (preventive) before or after a 5-week delay (therapeutic) after induction of hyperglycemia or at a lower dose (8 μg/kg of b.w. once per week) for 8 weeks (prolonged). Tail-nerve conduction velocities (NCV) was assessed at 5 and 11 weeks for the preventive and therapeutic schedule, respectively. Compared to nondiabetic rats, NCV was 20% lower after 5 weeks in the STZ group, and this decrease was attenuated 50% by rhEPO. Furthermore, the reduction of Na + ,K + -ATPase activity of diabetic nerves (by 55%) was limited to 24% in the rhEPO-treated group. In the therapeutic schedule, NCV was reduced by 50% after 11 weeks but by only 23% in the rhEPO-treated group. rhEPO treatment attenuated the decrease in compound muscle action potential in diabetic rats. In addition, rhEPO treatment was associated with a preservation of footpad cutaneous innervation, as assessed by protein gene product 9.5 immunostaining. Diabetic rats developed alterations in mechanical and thermal nociception, which were partially reversed by rhEPO given either in a preventative or therapeutic manner. These observations suggest that administration of rhEPO or its analogues may be useful in the treatment of diabetic neuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy
The Diabetes Control and Complications Trial Research Group. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-8-199504150-00001 · Cited by 602
Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy
Smith, A. G., Ramachandran, P., Tripp, S., & Singleton, J. R. (2001) · Neurology · doi:10.1212/wnl.57.9.1701 · Cited by 235
Cameron, N. E., Cotter, M. A., & Maxfield, E. K. (1993) · Diabetologia · doi:10.1007/bf00400231 · Cited by 181
Cited by
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
“A longer duration of diabetes can precipitate discernible nerve pathology in some diabetic rodent models (68, 283), with some loss of skin sensory fiber terminals (42, 93), in addition to sensory loss.”
BackgroundAxon degeneration mechanisms: Commonality amid diversity
Coleman, M. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1788 · Cited by 819
“Symptoms in diabetic neuropathy and acrylamide-induced peripheral neuropathy and axon degeneration in an in vitro model of HIV sensory neuropathy are reported to be alleviated by erythropoieti”
BackgroundDerivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic
Leist, M., Ghezzi, P., Grasso, G., Bianchi, R., Villa, P., Fratelli, M., Savino, C., Bianchi, M., Nielsen, J., Gerwien, J., et al. (2004) · Science · doi:10.1126/science.1098313 · Cited by 803
Self-citationKell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Emerging biological roles for erythropoietin in the nervous system
Brines, M., & Cerami, A. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1687 · Cited by 523
“and in animals with established diabetic neuropath”
Self-citationIntraepidermal nerve fiber density at the distal leg: a worldwide normative reference study
Lauria, G., Bakkers, M., Schmitz, C., Lombardi, R., Penza, P., Devigili, G., Smith, A. G., Hsieh, S., Mellgren, S. I., Umapathi, T., et al. (2010) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2010.00271.x · Cited by 518
Self-citationErythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic Retinopathy
Watanabe, D., Suzuma, K., Matsui, S., Kurimoto, M., Kiryu, J., Kita, M., Suzuma, I., Ohashi, H., Ojima, T., Murakami, T., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041773 · Cited by 484
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials
Calcutt, N. A., Cooper, M. E., Kern, T. S., & Schmidt, A. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2476 · Cited by 352
The non‐haematopoietic biological effects of erythropoietin
Arcasoy, M. O. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07014.x · Cited by 347
Erythropoietin as an antiapoptotic, tissue-protective cytokine
Ghezzi, P., & Brines, M. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401450 · Cited by 327
Self-citationThe role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets
Myers, R. R., Campana, W. M., & Shubayev, V. I. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03637-8 · Cited by 255
Endoplasmic Reticulum Stress Plays a Key Role in the Pathogenesis of Diabetic Peripheral Neuropathy
Lupachyk, S., Watcho, P., Stavniichuk, R., Shevalye, H., & Obrosova, I. G. (2013) · Diabetes · doi:10.2337/db12-0716 · Cited by 188
“The pathogenetic mechanisms of DPN include, but are not limited to, increased aldose reductase activity (4), advanced glycation/glycoxidation (5), oxidative-nitrative stress (6–12), activation of protein kinase C (13), poly(ADP-ribose) polymerase (14,15), cyclooxygenase2 (16), 12/15-lipoxygenase (17), and impaired neu…”
Kretz, A., Happold, C. J., Marticke, J. K., & Isenmann, S. (2005) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.04.009 · Cited by 184
The Brain Erythropoietin System and its Potential for Therapeutic Exploitation in Brain Disease
Hasselblatt, M., Ehrenreich, H., & Sir??n, A.-L. (2006) · Journal of Neurosurgical Anesthesiology · doi:10.1097/00008506-200604000-00007 · Cited by 159
Small fiber neuropathy: diagnosis, causes, and treatment
Sène, D. (2018) · Joint Bone Spine · doi:10.1016/j.jbspin.2017.11.002 · Cited by 113
Metadata
- Authors
- Bianchi, R., Buyukakilli, B., Brines, M., Savino, C., Cavaletti, G., Oggioni, N., Lauria, G., Borgna, M., Lombardi, R., Cimen, B., Comelekoglu, U., Kanik, A., Tataroglu, C., Cerami, A., & Ghezzi, P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-01-12
- Volume
- 101
- Issue
- 3
- Pages
- 823-828
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1980093324
- Cited by
- 248
- References
- 3
- FWCI
- 14.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.